BFEC
BMY.RT

Benjamin F. Edwards & Company’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,618
Closed -$2K – 1769
2020
Q4 		$2K Sell
3,618
-193
-5% -$411 ﹤0.01% 1555
2020
Q3 		$9K Sell
3,811
-350
-8% -$1K ﹤0.01% 1315
2020
Q2 		$15K Sell
4,161
-660
-14% -$2.38K ﹤0.01% 1197
2020
Q1 		$18K Sell
4,821
-2,575
-35% -$8.48K ﹤0.01% 1114
2019
Q4 		$22K Buy
+7,396
New +$19.2K ﹤0.01% 1213

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Benjamin F. Edwards & Company's BMY.RT Position: Q1 2021 in Review

Benjamin F. Edwards & Company sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,618 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $22K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Benjamin F. Edwards & Company reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 3,618 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2K.
  • Benjamin F. Edwards & Company first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Benjamin F. Edwards & Company's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $22K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2021, filed 14 May 2021.